Gael Morrow

I am currently involved in two research projects based on samples obtained from clinical trials. I work with Dr Nicola Curry and her team of clinicians at the Oxford Haemophilia and Thrombosis Centre at the Churchill Hospital.

The first project investigates two different types of fibrinogen replacement administered to trauma patients.  Fibrinogen is the key pro-coagulant factor required for stable clot formation. Patients recruited to the Fibrinogen Early in Severe Trauma StudY (FEISTY) were given one of two treatments: cryoprecipitate or fibrinogen concentrate. My research focuses on the differences in clot structure and strength between the two fibrinogens, and how this correlates with the clinical outcome.

The Intensive Care Study Of Coagulopathy 2 (ISOC-2) clinical trial recruited patients admitted to critical care that had abnormal clotting. Several interesting patient sub-groups arised, a group of particular interest is those with chronic liver disease.  A novel thrombin generation analyser will be used to investigate the role of the thrombomodulin : protein C pathway in predicting haemostatic balance and may be useful for assessment of disease progression in patients with liver disease.